An efficient one step, retro-biomimetic procedure for the synthesis of natural products having the atisane structure is described (Scheme 2), natural products which are components of medicinal plants and possess relevant biological activity. Their structures were confirmed by chemical transformations and spectral data. The starting materials were the known ent-kaur-16-en-19-oic acid (1) and ent-trachyloban-19-oic acid (2), diterpenoids readily available from the waste of sunflower.Introduction. -Tetracyclic atisanes, beyeranes, kauranes, and pentacyclic trachylobanes represent an important group of biosynthetically closely related polycyclic diterpenes, many of which display a wide range of biological activities [1 -7]. According to the hypothesis of diterpene biogenesis [8], diterpenes belonging to the families of ent-beyerene (A), ent-kaurene (B), ent-trachylobane (C), and ent-atisene (D) might all arise from (À)-copalyl pyrophosphate E via nonclassical carbocations such as F as common intermediates (Scheme 1). This hypothesis [8] has been formulated on the basis of the known isoprene rule and, to the best of our knowledge, has not been turned down yet. Scheme 1 provides a general overview of this biogenetic scheme, and our primary intention was to perform the retro-biomimetic transformation of ent-kaurene (B) to ent-beyerene (A) or ent-atisene (D) (path B ! F ! A or D).The rearrangements of ent-kaurane-and ent-trachylobane-type diterpenes have been reported under the action of different reagents [9]. Most of the examples relate on the reactions involving the formation of the nonclassical carbocation of type F (Scheme 1). It is well-known from the work of Olah and co-workers [10] that superacids are very convenient generators of these species, and our own experience on the use of fluorosulfuric acid (¼ fluorosulfonic acid; FSO 3 H) as an efficient promoter of terpenoid cyclizations [11 -15] and rearrangements [16 -18] provided a motivation to investigate the behavior of ent-kaur-16-en-19-oic acid (1) [19] and ent-trachyloban-19-oic acid (2) under superacid treatment (Scheme 2).